There is no answer here that an FDA label can settle, because ipamorelin has never been approved for human use and no manufacturer prescribing reference defines a dose, schedule, or standard of care. Everything documented about how it is dosed comes from research protocols, compounding-pharmacy practice, and off-label clinical use, and the honest bottom line is that none of these conventions is a validated standard. The molecule is a synthetic pentapeptide acting as a selective ghrelin-receptor agonist and growth hormone secretagogue, supplied as a lyophilized powder, reconstituted with bacteriostatic water, and reported in the off-label record as a subcutaneous injection.
Ipamorelin has no FDA-approved human dose, and the figures that circulate, commonly 100 to 300 micrograms per subcutaneous injection, come entirely from off-label practice and research protocols rather than an approved prescribing reference.
What the off-label record describes is almost exclusively subcutaneous injection, with the solution delivered into the fatty layer just beneath the skin rather than into muscle or by mouth. Oral delivery is reported as impractical because the peptide is degraded by digestive enzymes and poorly absorbed across the gut, while the subcutaneous route provides slow, gradual uptake that shapes how quickly the secretagogue reaches the pituitary. This is documentation of a reported technique, not a procedure recommended for anyone to perform.
The off-label record describes ipamorelin given by subcutaneous injection with a 29 to 31 gauge insulin syringe into rotated sites of accessible fat, because oral dosing fails when digestive enzymes degrade the peptide.
Reconstitution is the step that converts the freeze-dried powder into an injectable liquid, and the published practice describes bacteriostatic water as the diluent, sterile water carrying a small amount of benzyl alcohol that suppresses microbial growth and allows a multi-use vial to be drawn from over several days. The volume of diluent is reported as a deliberate concentration choice rather than an arbitrary one, since it sets how each unit mark on an insulin syringe maps to a microgram amount. The arithmetic is what makes the dose measurable.
| Step | What the record describes | Why it matters |
|---|---|---|
| Diluent | Bacteriostatic water with benzyl alcohol | Suppresses microbial growth across multi-day use |
| Concentration | 2 mL added to a 5 mg vial yields 2.5 mg/mL | Maps each syringe unit to a known microgram dose |
| Technique | Water run down the vial wall, gentle swirl, no shaking | Harsh agitation and foaming can damage fragile peptide chains |
| Inspection | Solution should be clear and particulate-free | Cloudiness or floating matter is cited as a reason to discard |
Published protocols describe reconstituting lyophilized ipamorelin with bacteriostatic water at a deliberate concentration, such as 2 mL into a 5 mg vial for 2.5 mg/mL, swirled gently rather than shaken because agitation degrades the peptide chain.
The published storage practice differs sharply between the dry powder and the reconstituted liquid, and that distinction is the part most often blurred. In sealed lyophilized form the powder is reported as comparatively stable, commonly refrigerated but tolerant of brief room-temperature and shipping intervals, which is why vials are documented as arriving without active cooling. Once bacteriostatic water is added, the solution becomes far more perishable, and heat, light, and repeated temperature swings are described as driving oxidation and breakdown of the amino acid chain.
The published record describes lyophilized ipamorelin powder as comparatively stable under refrigeration while the reconstituted solution is far more perishable, refrigerated at 2 to 8 degrees Celsius and cited as usable for roughly two to four weeks.
Because no regulator has approved ipamorelin for human use, there is no authoritative dose, and the numbers in circulation come from research protocols and off-label accounts rather than a label. The most commonly cited off-label amounts fall in the low-microgram range per injection, often described around 100 to 300 micrograms, sometimes summarized as roughly 200 to 300 micrograms once to a few times daily, with wide variation by source. Formal research more often expresses the dose relative to body weight, on the order of micrograms per kilogram, a more rigorous way to study a secretagogue's pituitary response than a fixed flat amount.
Off-label sources most often cite ipamorelin in the 100 to 300 microgram range per injection while formal research expresses it in micrograms per kilogram, and a finite ghrelin-receptor saturation ceiling means very large single doses add little additional growth hormone pulse.
In the off-label literature, timing is treated as nearly as important as the dose, because the stated goal is to amplify the body's own pulsatile growth hormone release rather than work against it. A fasted state is generally described around the injection, since elevated blood glucose and the insulin response after a meal blunt growth hormone secretion, which is why many protocols document spacing the injection roughly an hour or more from food on either side. Bedtime dosing is especially common in these accounts because the largest natural growth hormone pulse occurs during early deep sleep.
Off-label timing conventions favor a fasted state and bedtime administration, intended to reinforce the largest natural growth hormone pulse during early deep sleep, but these conventions rest on physiology-based reasoning rather than controlled human dosing trials.
Cycling means deliberately alternating periods of use with periods of rest rather than dosing continuously, and the off-label record describes it as a central feature of long-term use. The reasoning that appears in these accounts rests on receptor biology: sustained, uninterrupted stimulation of the ghrelin receptor is described as making the pituitary less responsive over time, so an unbroken regimen risks diminishing returns where the same dose produces a smaller pulse. The rest period is framed as letting receptor sensitivity recover, much as the body's natural pulsatile signaling depends on intervals of low activity.
Off-label accounts describe ipamorelin cycled in roughly eight-to-twelve-week use phases followed by multi-week breaks, on the reasoning that uninterrupted ghrelin-receptor stimulation reduces pituitary responsiveness, though none of these cycling schemes is a validated medical protocol.
The pairing of ipamorelin with CJC-1295 is documented because the two peptides act on different parts of the same pathway, and the off-label record describes the combination as producing a stronger, more coordinated growth hormone release than either alone. Ipamorelin is a ghrelin-receptor agonist that triggers a pulse and suppresses somatostatin, the hormone that normally restrains release, while CJC-1295 is a growth-hormone-releasing-hormone analog that directly stimulates the pituitary; the effect is often called synergistic rather than additive because one peptide amplifies the conditions the other works under. A key documented distinction is whether the CJC-1295 carries the DAC modification, which sets whether its timing matches ipamorelin's short action.
| Pairing factor | CJC-1295 with DAC | CJC-1295 without DAC (modified GRF) |
|---|---|---|
| Half-life | Long; dosed once or twice weekly | Short; matches ipamorelin's duration |
| Fit with ipamorelin | Clashes with ipamorelin's short action | Supports daily co-administration |
| Reported co-dosing | Timing mismatch limits same-syringe use | Often drawn together, fasted bedtime window |
The off-label record pairs ipamorelin with CJC-1295 without DAC, a short-acting modified GRF whose duration matches ipamorelin's, because the ghrelin-receptor agonist and the GHRH analog act on different parts of the same pathway for a synergistic pulse, while the long-acting DAC form clashes with ipamorelin's short action.
Educational use only. This article describes what the published scientific and clinical literature reports about Ipamorelin. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
